Oramed Pharmaceuticals’ CEO Issues Letter to Shareholders

JERUSALEM, Jan. 19, 2018 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com) Dear Shareholders, All the hard work and dedication in 2017 has successfully positioned Oramed to initiate a U.S. based multicenter 90-day treatment study under a FDA IND focused on the lowering of HbA1c in type 2 diabetic patients later this quarter. This is […]